Development Disorders

Main Content

enligGHten Study

Study title

Multi-center, phase 3, long-term, open label trial investigating safety and efficacy of TransCon hGH administered once-weekly in children with growth hormone deficiency (GHD) who have completed a prior TransCon hGH clinical trial

  • Principal Investigator: Dr. Naznin Dixit


This study is looking to assess long-term safety and efficacy of an experimental drug in children with GHD previously treated in a phase 3 experimental drug trial.

Who can participate

Those eligible to participate in this study include:

  • Children with GHD, completing a prior phase 3 experimental drug trial, still taking study drug

For more information

  • Deepali Bhatt
    University of Mississippi Medical Center 
    2500 N. State St. 
    Jackson MS 39216 
    (601) 815-9481
  • IRB Number: 2018-0106